Loading...
JBM (Healthcare) Limited
2161.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$2.95
HK$-0.01(-0.34%)
JBM (Healthcare) Limited (2161.HK) AI-Powered Stock Analysis
See how JBM (Healthcare) Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerJBM (Healthcare) Limited (2161.HK) Stock Overall Grade
JBM (Healthcare) Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B+
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to JBM (Healthcare) Limited's overall stock rating.
Forecast
C+Score
55/100Financial Growth
CScore
40/100Fundamental Growth
B+Score
79/100Key Ratios
A+Score
94/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100JBM (Healthcare) Limited (2161.HK) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (79/100, B+) highlight its stability, while Key Ratios (94/100, A+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each JBM (Healthcare) Limited stock grade, including financials, comparisons, and forecasts.